Affibody Medical AB

Prenumeration

Filter

År

Typ

Språk

2023-03-18 15:00:00 Izokibep Phase 2b/3 Hidradenitis Suppurativa Data Presented at the 2023 American Academy of Dermatology Annual Meeting

2023-03-18 15:00:00 Resultat från fas 2b/3-studie av izokibep vid behandling av hidradenitis suppurativa presenteras vid 2023 års American Academy of Dermatology Annual Meeting

2023-03-07 10:00:00 Affibody och Chiesi Group ingår samarbete för att utveckla och kommersialisera innovativa behandlingar av luftvägssjukdomar

2023-03-07 10:00:00 Affibody and Chiesi Group collaborate to develop and commercialize innovative treatments for respiratory diseases

2023-01-05 13:00:00 Positive Top-line Clinical Data for Izokibep in Hidradenitis Suppurativa

2023-01-05 13:00:00 Positiva initiala kliniska resultat med izokibep i hidradenitis suppurativa

2023-01-04 08:00:00 First HER2-low patients enrolled in Phase 2 basket trial using Affibody’s PET imaging agent ABY-025

2023-01-04 08:00:00 Fas 2-studie initierad med Affibodys PET-diagnostiska substans ABY-025 i patienter med lågt HER2-uttryck

2022-12-23 08:00:00 Affibody signs €20 million loan agreement with the EIB to finance the development of next generation’s biopharmaceuticals against cancer and inflammatory diseases

2022-12-23 08:00:00 Affibody undertecknar låneavtal på 20 miljoner euro med EIB för att finansiera utvecklingen av nästa generations bioläkemedel mot cancer och inflammatoriska sjukdomar

2022-11-08 16:00:00 Affibody Announce Positive Additional Izokibep Phase 2 Data in Patients with Psoriatic Arthritis (PsA) will be Presented at American College of Rheumatology (ACR) Convergence 2022

2022-11-07 15:20:00 Affibodys partner Rallybio rapporterar positiva data från fas 1-studie med RLYB116

2022-11-07 15:20:00 Affibody’s partner Rallybio Announces Positive Phase 1 Results for RLYB116

2022-06-03 11:15:00 Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During EULAR

2022-05-19 14:50:00 Report from Annual General Meeting in Affibody Medical AB (publ)

2022-01-12 08:00:00 Lokon Pharma och Affibody inleder samarbete för att utveckla nya cancerterapier

2022-01-12 08:00:00 Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics

2021-12-14 08:00:00 Affibody AB, ACELYRIN, INC. and Inmagene Announce Positive Interim Results from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis

2021-12-14 08:00:00 Affibody AB, ACELYRIN, INC. och Inmagene meddelar positiva interimdata från en global fas 2-studie av izokibep i patienter med psoriasisartrit

2021-12-09 08:00:00 Phase 2 HER2-targeting Study Presented at SABCS

2021-12-09 08:00:00 Klinisk fas 2-studie med HER2-riktad behandling presenteras vid SABCS

2021-11-16 08:00:00 Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties

2021-11-16 08:00:00 Affibody ingår avtal med ACELYRIN för utvecklingen och kommersialiseringen av izokibep till ett totalt värde om 305 miljoner USD och royalties

2021-03-15 08:00:00 Årsredovisning 2021 (Swedish)

2021-03-15 08:00:00 Annual Report 2021

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode